A prospective, randomized, open-label clinical trial evaluating the effect of sarpogrelate hydrochloride on skin perfusion pressure in hemodialysis patients with arteriosclerosis obliterans

A prospective, randomized, open-label clinical trial evaluating the effect of sarpogrelate hydrochloride on skin perfusion pressure in hemodialysis patients with arteriosclerosis obliterans - A prospective, randomized, open-label clinical trial evaluating the effect of sarpogrelate hydrochloride on skin perfusion pressure in hemodialysis patients with arteriosclerosis obliterans

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003597

Enrollment

Registered

2010-05-17

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Patients will be randomly assigned either to sarpogrelate hydrochloride or conventional therapy. Sarpogrelate hydrochloride 300mg daily for a year Conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Hemodialysis patients with arteriosclerosis obliterans(Fontaine1)2)SPP<75mmHg at the commencement

Exclusion criteria

Exclusion criteria: 1)Patients with revascularization 2)Patients who is taking antiplatelet agents excluding low-dose aspirin and/or thienopyridine derivatives 3)Patients with warfarin 4)Patients with coronary artery disease and/or cerebrovascular disease within three months 5)Patients with bleeding or bleeding tendency 6)Patients with severe hepatic dysfunction and/or cardiac dysfunction 7)Patients with malignancy 8)Pregnant or lactating women, or women who wish to become pregnant 9)Patients with allergy to sarpogrelate hydrochloride 10)Patients who were not suitable for this trial judged by the attending doctor

Design outcomes

Primary

Measure	Time frame
Change in SPP	—

Secondary

Measure	Time frame
Improvement of symptoms of ASO Change in ABI Adverse event	—

Countries

Japan

Contacts

Public ContactTakatoshi Kakuta

Department of Internal Medicine, Tokai University School of Medicine Kidney. Center

0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026